Ubs Oncology Impact Fund L.p. - Net Worth and Insider Trading
Ubs Oncology Impact Fund L.p. Net Worth
The estimated net worth of Ubs Oncology Impact Fund L.p. is at least $208 Million dollars as of 2024-11-13. Ubs Oncology Impact Fund L.p. is the 10% Owner of ITeos Therapeutics Inc and owns about 22,638,547 shares of ITeos Therapeutics Inc (ITOS) stock worth over $208 Million. Details can be seen in Ubs Oncology Impact Fund L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ubs Oncology Impact Fund L.p. has not made any transactions after 2022-01-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Ubs Oncology Impact Fund L.p.
Ubs Oncology Impact Fund L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ubs Oncology Impact Fund L.p. owns 10 companies in total, including Oncorus Inc (ONCR) , ITeos Therapeutics Inc (ITOS) , and TCR2 Therapeutics Inc (TCRR) among others .
Click here to see the complete history of Ubs Oncology Impact Fund L.p.’s form 4 insider trades.
Insider Ownership Summary of Ubs Oncology Impact Fund L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCR | Oncorus Inc | 2020-10-01 | 10 percent owner |
| ITOS | ITeos Therapeutics Inc | 2022-01-05 | other: X* |
| TCRR | TCR2 Therapeutics Inc | 2019-02-13 | 10 percent owner |
 | | 2019-02-07 | 10 percent owner |
| | 2017-11-02 | 10 percent owner |
| | 2017-03-25 | 10 percent owner |
| | 2017-10-27 | 10 percent owner |
| | 2017-03-25 | 10 percent owner |
| | 2021-04-29 | 10 percent owner |
| | 2021-01-07 | 10 percent owner |
Ubs Oncology Impact Fund L.p. Latest Holdings Summary
Ubs Oncology Impact Fund L.p. currently owns a total of 1 stock. Ubs Oncology Impact Fund L.p. owns 22,638,547 shares of ITeos Therapeutics Inc (ITOS) as of January 5, 2022, with a value of $208 Million.
Latest Holdings of Ubs Oncology Impact Fund L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ITOS | ITeos Therapeutics Inc | 2022-01-05 | 22,638,547 | 9.20 | 208,274,632 |
Holding Weightings of Ubs Oncology Impact Fund L.p.
Ubs Oncology Impact Fund L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Ubs Oncology Impact Fund L.p. has made a total of 19 transactions in ITeos Therapeutics Inc (ITOS) over the past 5 years, including 1 buys and 18 sells. The most-recent trade in ITeos Therapeutics Inc is the sale of 245,469 shares on January 5, 2022, which brought Ubs Oncology Impact Fund L.p. around $10 Million.
Insider Trading History of Ubs Oncology Impact Fund L.p.
- 1
Ubs Oncology Impact Fund L.p. Trading Performance
GuruFocus tracks the stock performance after each of Ubs Oncology Impact Fund L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ubs Oncology Impact Fund L.p. is 24.95%. GuruFocus also compares Ubs Oncology Impact Fund L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Ubs Oncology Impact Fund L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ubs Oncology Impact Fund L.p.'s insider trading performs compared to the benchmark.
Performance of Ubs Oncology Impact Fund L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 62.69 | | | | | |
| Relative Return to S&P 500(%) | 53.69 | | | | | |
Ubs Oncology Impact Fund L.p. Ownership Network
Ownership Network List of Ubs Oncology Impact Fund L.p.
Ownership Network Relation of Ubs Oncology Impact Fund L.p.
Ubs Oncology Impact Fund L.p. Owned Company Details
What does Oncorus Inc do?
Who are the key executives at Oncorus Inc?
Ubs Oncology Impact Fund L.p. is the 10 percent owner of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .
Oncorus Inc (ONCR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncorus Inc Insider Transactions
Ubs Oncology Impact Fund L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Ubs Oncology Impact Fund L.p.. You might contact Ubs Oncology Impact Fund L.p. via mailing address: 450 Kendall Street, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
